Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VBY-376 is a small molecule drug developed by Virobay for the treatment of hepatitis C and other liver-related diseases. It acts as an inhibitor of cathepsin B (CTSB) and the hepatitis C virus (HCV) nonstructural proteins NS3 and NS4, which are proteases essential for viral replication. The drug was investigated primarily as an antiviral agent targeting HCV infection, with additional development efforts in hepatic fibrosis and non-alcoholic steatohepatitis. Clinical trials included phase 1 studies evaluating safety and pharmacokinetics in healthy adults[1][2][3][4]. Development for hepatitis C has been discontinued, while no further development has been reported for hepatic fibrosis or non-alcoholic steatohepatitis[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VBY-376.